Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the ...

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...

Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based inv ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced that safety and efficacy ...

Unfortunately, I have been diagnosed many years back with Retinal Dystrophy ( genetic mutation ). The condition has NO treatment available and it decreased my vision constantly, leading to my ...

Bietti crystalline dystrophy (BCD) is a rare inherited retinal disease primarily caused by mutations in the CYP4V2 gene. This condition leads to progressive vision loss due to the degeneration of ...

James L. Warnken, a Stark County resident who was diagnosed with genetic retinal dystrophy at age 9, is a digital marketing & digital accessibility specialist with Apex Communications Network.

REGENXBIO is a longtime player in the gene therapy space, but one that’s yet to bring its own therapy to market (in the early ...